a disease of unknown etiology, is in some patients severe, extremely debilitating, and unresponsive to conventional therapies, including UV-B, oral psoralen with long-wave UV radiation in the A range (PUVA), oral retinoids, and methotrexate. We report the results from our study of seven patients with refractory psoriasis who were treated with the new immunosuppressive drug, tacrollmus (FK 506).
• Background.-Psoriasis, a disease of unknown etiology, is in some patients severe, extremely debilitating, and unresponsive to conventional therapies, including UV-B, oral psoralen with long-wave UV radiation in the A range (PUVA), oral retinoids, and methotrexate. We report the results from our study of seven patients with refractory psoriasis who were treated with the new immunosuppressive drug, tacrollmus (FK 506).
Observstions.-AII seven patients showed a dramatic resolution of psoriasis that remained in remission as long as they received full-dose therapy. Serial skin biopsy specimens demonstrated a rapid disappearance of the inflammatory infiltrate and a slower resolution of the epidermal changes. Tacrolimus was well tolerated during the 5.5 to 14 months of observation. Side effects, including nephrotoxicity and hypertension, were controlled by appropriate modification of drug dosage.
Conclusions.-Tacrolimus, a new immunosuppressive agent, is effective in treating patients with severe recalcitrant psoriasis. The mechanism of Its action in psoriasiS is unknown, but it may be related to Its ability to modulate immune function. Further studies will establish criteria for patient selection and drug dosage, to maximize efficacy of this agent in psoriaSiS, while minimizing its toxicity.
(Arch Dermatol. 1992; 128:781-785) P soriasis. a common heritable disease that affects the skin, the joints, or both, has many characteristics of an immunologically mediated disease. Included among these characteristics are a variable HLA association, lymphocytic infiltration of skin lesions. and evidence of cytokine actiyity or increased expression of new antigens during exacerbations. I.:! Circumstantial eyjdence for an immune etiology is the striking remission of psoriatic lesions that can be achieved with cyclosporine/" an immunosuppressive drug whose use for this purpose has been limited its by nephrotoxicity, hypertension, and other dose-related side effects. We report our experience with tacrolimus (FK 506), another immunosuppressive drug that is unrelated chemically to cyclosporine but also. inhibits helper T -lymphocyte activation and the syntheSIS and expression of cytokines.Ii.~ Encouraging results with tacrolimus have been reported in trials of whole organ transplantation."'1II
PATIENTS AND METHODS
Clinical features are summarized in Table 1 . Amelioration of psoriasis in four patients was incidental to the primary objective, preventing organ rejection of heart (one patient) or Ii ver transplantation (three patients). The liwr disease in one of the latter patient:; was caused by high-dose methotrexate :;odium treatment fol' psoriasis during a 2-year period. The other three patient:; had ~e\'ere recalcitrant p:;orimii:; that had resisted the therapies listed in Table 1 .
Psoriasis Evaluation
The :;everity of psoriasi:; wa:; quantitated using the Psoriasis Area and Severity Index.:·· 11 The assessment is performed by measuring the extent of :;kin involvement and the amount of erythema. infiltration. and desquamation using a scale of 0 to 4 (0 indicates none: 
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\'ere: and -I. \'erv :;e\·ere). Each of the abo\'e clinical :,iI..'l1:' \\'a,; given an appropriate :'core and a tompo,:ite additive ~umh(>r obtained that repre:,ent~ the P~oria:;i,; Area and Se\'erit~· Index. In the three patients whose primary dia!£l1o:;i:; wa,; p:,oriasis. biopsy specimens were obtained before institutin~ treatment. 2 weeks later. and when they were clinically free of lesions.
Dose Control
Oral tacrolimus therapy was started at 0.15 mgikg. t\\;ce daily. in the patients who did not receive organ tran~plants ,.
and the do~age was adjusted. as necessary, according to tacrolimus plasma levels. Plasma levels were measured at a 12-hour trough using an enzyme-linked immunoassay.l~ Similar dosage adjustments were made when clinical evidence indicated incomplete disease control or toxic reactions. No other antipsoriatic therapy was used. The transplant recipients were initially administered intravenous doses of 0.075 or 0.10 mgfkg tacroiimus per day and converted to therapy with oral medications when they could begin oral feeding. Patients who had received transplants also received prednispne initially, doses of which were tapered to levels shown in Table 2 at the time of their last follow-up \'isit. 
Side Effect Surveillance
Extensive medical examinations. including complete neurologic assessments. were performed repeatedly. Results of renal function tests and levels of serum cholesterol. uric acid. blood glucose. serum magnesium. and other electrolytes were carefully monitored. Development of high blood pressure (if present) was quantitated by the number of antihypertensive drugs required to maintain a normotensi\'e state. Hyperkalemia. if it occurred, was treated with the mineralocorticoid. fludrocortisone acetate. Hypomagnesemia seen in some patients did not require correction. 
RESULTS

Effect on Psoriasis
There was a marked reduction in erythema and scale in all seven patients at the end of 1 week and complete clinical remission within 4 weeks (Fig 1) . The remissions ha\'e been sustained in all patients. Our follow-up periods range from 5.5 to 14 months. Interpretation of the beneficial effect of tacrolimus was straightforward in the three patients whose primary diagnosis was psoriasis (Table 3) because they were not given systemic corticosteroids or other antipsoriatic medications. Improvement of psoriatic arthritis, with reduction in stiffness, pain on movement. and swelling, also occurred simultaneously in all three patients. Serial skin biopsy specimens obtained from the active plaques of psoriasis demonstrated a rapid disappearance of the inflammatory infiltrate in the dermis and the neutrophib in the stratum corneum (Fig 2) . The h~'perkera tosis and epidermal acanthosis took longer to re\'ert to normal (Table 3 ). Efforts to reduce tacrolimus dosage in these three patients resulted in the rapid reappearance of early psoriatic skin lesions. which promptly resolved on returning to the immediately prior dose of tacrolimus.
The foul' patients who had organ transplants recei\'ed systemic prednisone therapy postoperatively. but their remission persisted after lowering (patient :~) or stopping (patifnt,,; 1. 2. and -!) the corticosteroid therapy (Table 2J . Se\'eral months postoperativel~', when there was no evidence of graft dysfunction. the liver recipient whose end-stage hepatic disease was caused by methotrexate therapy (patient 2) had small psoriatic plaques develop neal' the exit ,,;ite of his T tube. These psoriatic plaques disappeared \\'ith a minor increase in tacrolimus dose.
Toxicity and Metabolic Changes
Tacrolimus dosage. plasma levels. and sUl'\'eillance measurements were similar in patients who had and did not have transplants. Transient trembling, paresthesias. and insomnia not requiring tacrolimus dose 784 Arch Dermatol-Vol 128. June 1992 changes were noted in three patients. Increases of serum creatinine or serum urea nitrogen levels signaled the need for downward dose adjustments. Most patients required a decrease of 10% to 25% of the total dose. Despite careful monitoring of dosage, serum creatinine and serum urea nitrogen levels increased at our check points (Table 2) . Although generally stable, the final levels of these measures were higher in all patients when compared -with pretreatment values. Three patients had development of arterial hypertension that was controlled -with single antihypertensive drug therapy; one patient who initially required two antihypertensive drugs was later normotensive with no drugs, and one patient with preexisting hypertension requiring one drug for control had no change while receiving tacrolimus therapy.
COMMENT
Tacrolimus caused a complete remission of psoriasis in all seven treated patients. Improvement was always evident within a few days. In the patients who did not have transplants, tacrolimus dose and plasma levels needed to maintain remission of psoriasis were in the same range as those required to prevent allograft rejection. Efforts to reduce the dose of tacrolimus in these patients resulted in reactivation of the psoriasis. In one liver recipient (patient 2), dose reduction caused a minor recurrence of psoriasis without evidence of b'Taft rejection.
Whether the reward of complete control of psoriasis will be worth the risk of long-term therapy with this powerful drug can be judged only after future studies. The first administration of tacrolimus to a human to prevent organ rejection occurred only 29 months ago. 1i Our patients with psoriasis. whose cases are reported herein, have been treated with tacrolimus for 5.5 to 14 months. The results are very encouraging. The only potentially serious side effect was nephrotoxicity. In patients with psoriasis as their primar~' disease. serum creatinine levels increased 27':( to 111 r( (mean, G8,:() above baseline early in their course. but later stabilized at 66% to 74% (me~n. G8O/C) above pretreatment levels. In the patients with psoriasis who also underwent organ transplantation, serum creatinine le\'els increased 100% to 200% (mean. 152q) abO\"e baseline. but later stabilized at :-\:-)('r to 20W, (mean. l!i(jr() abo\'e pretreatment values. Patients \\'ho are candidates for organ transplantation lIsuall~' have some deg1'ee of incipient renal compromise. which may ha \'to, predisposed them to greater tacrolimus nephrotoxic reactions, Elevations in serum creatinine and serum urea nitrogen levels responded to close reduction and reached an increased but stable state at the surveillance check points. No patient has had an infection. The patients \\ith psoriasis who did not ha\'e transplants who were accepted for our study were those who had severe. widespread treatment-resistant disease that completely ruined their quality of life. Patients v.ith less severe disease are not candidates for treatment with tacrolimus until further experience regarding the severity and long-term effects of nephrotoxic reactions are understood.
Tacrolimus-Jegasothy et al
The remarkable efficacy of tacrolimus in psoriasis is attributable to its effect on immune modulation. Howe'-er .. this may not be the sole explanation for its effect. I t is knovm that the cytosolic receptors for this drug (called "FK binding protein") as well as the distinct cyclosporine-binding site (cyclophilin) are part of a pre,-ious!y unrecognized class of small molecular '\'eight proteins collectively called "immunophilins." These proteins are found in the cytoplasm of essentially all eukaryotic cells, including those of the skin. from the !()\\'est to highest species. including man.I:l The binding of these immunophilins with cyclosporine, tacrolimus, and presumably other drugs can affect signal transduction in nonimmunologic as well as immunoregulatory cells. Thus, an array of metabolic consequences could result affecting growth control as has been demonstrated in the liver.14 Growth control in the skin cannot be excluded as a target of such nonimmunologic effects.
